+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Respiratory Partnering 2014-2019: Deal trends, players and financials

  • ID: 2229065
  • Report
  • Region: Global
  • 200 Pages
  • CurrentPartnering
1 of 4
the Global Respiratory Partnering 2014-2019: Deal Trends, Players and Financials Report Provides Comprehensive Understanding and Unprecedented Access to the Respiratory Partnering Deals and Agreements Entered Into by the World's Leading Healthcare Compani

FEATURED COMPANIES

  • 3M Drug Delivery Systems
  • Biogen
  • Evotec
  • Johns Hopkins University
  • Omdana Therapeutics
  • SkyePharma
  • MORE
Global Respiratory Partnering 2014 to 2019 provides the full collection of Respiratory disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.
  • Trends in Respiratory partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Respiratory partnering agreement structure
  • Respiratory partnering contract documents
  • Top Respiratory deals by value
  • Most active Respiratory dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Respiratory disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Respiratory deals.

The report presents financial deal terms values for Respiratory deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Respiratory dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Respiratory dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Respiratory deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Respiratory dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Respiratory deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Respiratory partnering deals by specific Respiratory target announced since 2014. The chapter is organized by specific Respiratory therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Respiratory partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Respiratory partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Respiratory technologies and products.

Report Scope

Global Respiratory Partnering 2014 to 2019 is intended to provide the reader with an in-depth understanding and access to Respiratory trends and structure of deals entered into by leading companies worldwide.

Global Respiratory Partnering 2014 to 2019 includes:
  • Trends in Respiratory dealmaking in the biopharma industry since 2014
  • Analysis of Respiratory deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Respiratory deal contract documents
  • Comprehensive access to over 300 Respiratory deal records
  • The leading Respiratory deals by value since 2014
  • Most active Respiratory dealmakers since 2014
The report includes deals for the following indications: Allergic rhinitis, Acute respiratory distress syndrome, Asthma, Bronchitis, Chronic obstructive pulmonary disease, Emphysema, Idiopathic pulmonary fibrosis, Occupational Lung Disease, Asbestosis, Coalworkers pneumoconiosis, Hypersensitivity pneumonitis, Silicosis, Pneumonia, Pulmonary arterial hypertension, Pulmonary embolism, Respiratory Tract Infection, Sarcoidosis, Sinusitis, Breathlessness, Bronchospasm, Chest Pain, Cough, Nasal congestation, Snoring, Wheeze, plus other respiratory indications.

In Global Respiratory Partnering 2014 to 2019, available deals and contracts are listed by:
  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Respiratory Partnering 2014-2019 report provides comprehensive access to available deals and contract documents for over 400 respiratory deals. Analyzing actual contract agreements allows assessment of the following:
  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?
Global Respiratory Partnering 2014 to 2019 provides the reader with the following key benefits:
  • In-depth understanding of Respiratory deal trends since 2014
  • Access Respiratory deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Respiratory partner companies
  • Comprehensive access to over 300 links to actual Respiratory deals entered into by the world’s biopharma companies
  • Indepth review of Respiratory deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Respiratory opportunities
  • Uncover companies actively partnering Respiratory opportunities
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 3M Drug Delivery Systems
  • Biogen
  • Evotec
  • Johns Hopkins University
  • Omdana Therapeutics
  • SkyePharma
  • MORE
Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Respiratory dealmaking
2.1. Introduction
2.2. Respiratory partnering over the years
2.3. Respiratory partnering by deal type
2.4. Respiratory partnering by industry sector
2.5. Respiratory partnering by stage of development
2.6. Respiratory partnering by technology type
2.7. Respiratory partnering by therapeutic indication

Chapter 3 –Financial deal terms for Respiratory partnering
3.1. Introduction
3.2. Disclosed financials terms for Respiratory partnering
3.3. Respiratory partnering headline values
3.4. Respiratory deal upfront payments
3.5. Respiratory deal milestone payments
3.6. Respiratory royalty rates

Chapter 4 – Leading Respiratory deals and dealmakers
4.1. Introduction
4.2. Most active in Respiratory partnering
4.3. List of most active dealmakers in Respiratory
4.4. Top Respiratory deals by value

Chapter 5 – Respiratory contract document directory

5.1. Introduction
5.2. Respiratory partnering deals where contract document available

Chapter 6 – Respiratory dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Respiratory therapeutic target

Appendices
Appendix 1 – Directory of Respiratory deals by company A-Z 2014 to 2019
Appendix 2 – Directory of Respiratory deals by deal type 2014 to 2019
Appendix 3 – Directory of Respiratory deals by stage of development 2014 to 2019
Appendix 4 – Directory of Respiratory deals by technology type 2014 to 2019
Further reading on dealmaking
Deal type definitions

Table of Figures
Figure 1: Respiratory partnering since 2014
Figure 2: Respiratory partnering by deal type since 2014
Figure 3: Respiratory partnering by industry sector since 2014
Figure 4: Respiratory partnering by stage of development since 2014
Figure 5: Respiratory partnering by technology type since 2014
Figure 6: Respiratory partnering by indication since 2014
Figure 7: Respiratory deals with a headline value
Figure 8: Respiratory deals with upfront payment values
Figure 9: Respiratory deals with milestone payment
Figure 10: Respiratory deals with royalty rates
Figure 11: Active Respiratory dealmaking activity– 2014 to 2019
Figure 12: Top Respiratory deals by value since 2014
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 3M Drug Delivery Systems
  • 4D Molecular Therapeutics
  • 4D Pharma
  • AAM Healthcare
  • Abbvie
  • Acacia Research
  • Acorda Therapeutics
  • Actavis (name changed to Allergan)
  • Actelion
  • AdAlta
  • Adherium
  • ADM Tronics
  • Aerocrine
  • Aerogen
  • Afimmune
  • AirWare Labs
  • Airway Management
  • AIT Therapeutics
  • Ajad Medical
  • Akonni Biosystems
  • Akorn
  • Alana Healthcare
  • ALK-Abello
  • Allakos
  • Almirall
  • Alnylam Pharmaceuticals
  • Alpine Immune Sciences
  • American College of Chest Physicians
  • AMO Pharma
  • AmorChem
  • Analytics 4 Life
  • AnGes MG
  • Angiodynamics
  • ANI Pharmaceuticals
  • Anthem Bluecross
  • Apax Partners
  • Aptar Pharma
  • Aptuit
  • Aradigm
  • Aralez Pharmaceuticals
  • Arch Biopartners
  • Arcturus Therapeutics
  • Arena Pharmaceuticals
  • Aridis Pharmaceuticals
  • Ario Pharma
  • Aristea Therapeutics
  • Ark Biosciences
  • ARUP Laboratories
  • Aslan Pharma
  • Asthma UK
  • AstraZeneca
  • Athersys
  • Auven Therapeutics
  • Avita Medical
  • Ayasdi
  • AzarGen Biotechnologies
  • Battelle
  • Baxalta
  • Bayer
  • Becton Dickinson
  • Bellerophon Therapeutics
  • Bellus Health
  • Bicycle Therapeutics
  • Bill and Melinda Gates Foundation
  • Bina Technologies
  • Bio-Techne
  • bioCSL
  • Biogen
  • Biomedical Advanced Research and Development Authority
  • BioMed X Innovation Center
  • BioReliance
  • BirchBioMed
  • Blue Shield of California
  • Boehringer Ingelheim
  • Boston University School of Medicine
  • Breathe Active
  • Breath Therapeutics
  • Bridge Biotherapeutics
  • Brigham and Women's Hospital
  • Bristol-Myers Squibb
  • British Lung Foundation
  • California Institute for Biomedical Research
  • Camino Partnership
  • Canadian Institutes of Health Research
  • Caprion Proteomics
  • CARB-X
  • Cardiome Pharma
  • CareFusion
  • Cedars-Sinai Medical Center
  • Celdara Medical
  • Cell Therapy Catapult
  • Celon Pharma
  • Chiesi Farmaceutici
  • Chinese Future Industry Investment Fund
  • Cigna Healthcare
  • Cilag AG
  • Cincinnati Children’s Hospital Medical Center
  • Cipher Pharmaceuticals
  • Cipla
  • Circassia
  • CMC Biologics
  • Coalition for Epidemic Preparedness Innovations
  • Coating Place
  • Collplant
  • Columbia University Medical Center
  • Commense
  • CompleWare
  • Context Therapeutics
  • Cook Medical
  • COPD Foundation
  • Corsair Pharma
  • Cortex Pharmaceuticals
  • Covalon Technologies
  • CRS Bio
  • CSL
  • Cue Health
  • Cureveda
  • Curie-Cancer
  • Cyclopharm
  • Daewoong Pharmaceutical
  • Dalton Pharma Services
  • DefiniGEN
  • DEKA Research and Development
  • Department of Defense
  • Department of Health and Human Services
  • Discovery Laboratories
  • Dizal Pharmaceutical
  • Domainex
  • Dr. Reddy's Laboratories
  • Drukier Institute for Children's Health
  • DS Biopharma
  • Ducere Pharma
  • Duke Clinical Research Institute (DCRI)
  • Duke University
  • Eastar Industries
  • ECM Medical
  • Eiger BioPharmaceuticals
  • Electromed
  • Empatica
  • Erasmus University Medical Center
  • ETView Medical
  • European Commission
  • European Union
  • Everest Medicines
  • EvoRX Technologies
  • Evotec
  • Exalenz Bioscience
  • Exco InTouch
  • Faes Farma
  • Faron Pharmaceuticals
  • Fedora Pharmaceuticals
  • Fibrocor Therapeutics
  • Flemish agency for Innovation by Science and Technology
  • Flextronics
  • Forge Therapeutics
  • Fred Hutchinson Cancer Research Center
  • French National Research Agency
  • FSC Laboratories
  • Fujifilm Diosynth Biotechnologies
  • Galapagos
  • Galecto Biotech
  • Galvani Bioelectronics
  • GE Healthcare
  • Geisinger Health System
  • GEn1E Lifesciences
  • Genentech
  • GeneOne Life Science
  • Genome Institute of Singapore
  • Genten Therapeutics
  • German Government
  • Gilead Sciences
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • Government of Australia
  • Guangzhou Institute of Respiratory Disease
  • Halyard Health
  • Haplogen
  • Harvard Apparatus Regenerative Technology
  • Harvard Stem Cell Institute
  • Harvest Capital Strategies
  • Healios K.K.
  • Healthcare 21
  • HealthPrize Technologies
  • HealthTrust Purchasing Group
  • Hebrew University of Jerusalem
  • Hemovent
  • Heptares Therapeutics
  • Highmark Blue Shield
  • Horizon 2020
  • Hovione
  • Humanetics
  • iBio
  • IBM
  • Icagen
  • Icahn School of Medicine at Mount Sinai
  • IDbyDNA
  • Ideal Life
  • IDT Biologika
  • Ikaria
  • Imbio
  • IMI
  • Impact Instrumentation
  • Imperial College London
  • Industrial Technology Research Institute
  • Inhibrx
  • Innovate UK
  • Innovative Genomics Initiative (IGI)
  • Innovative Medicines Initiative (IMI)
  • Innovus Pharmaceuticals
  • INO Therapeutics
  • Inovio Pharmaceuticals
  • Insmed Inc
  • InspiRX Pharma
  • Integrated Diagnostics
  • Integrated Vent Solutions
  • Intrexon
  • Inventiva
  • Invion
  • Jackson Laboratory
  • Janssen Biotech
  • Janssen Pharmaceuticals
  • Janssen Research & Development
  • Janssen Sciences
  • JHL Biotech
  • Johns Hopkins University
  • Johnson & Johnson Innovation
  • Jubilant DraxImage
  • Kamada
  • KineMed
  • Knopp Biosciences
  • Kyorin Pharmaceutical
  • Laboratory Corporation of America
  • Laurel Venture Capital
  • Lawson Health Research Institute
  • Lee's Pharmaceutical
  • LFB Biotechnologies
  • LifeArc
  • Ligand Pharmaceuticals
  • Locus Biosciences
  • Luminex
  • Lung Biotechnology
  • Lung Transplant Foundation
  • Lupin Limited
  • Lupin Pharmaceuticals
  • Lyomark Pharma
  • MannKind Biopharmaceuticals
  • Masimo
  • Massachusetts General Hospital
  • Maxor National Pharmacy
  • Mayo Clinic
  • McKesson
  • Medical Developments International
  • Medical International Research
  • Medical Research Council
  • Medical University of South Carolina
  • Medical University South Carolina
  • MedImmune
  • MediPines
  • Medtronic
  • Meiji Seika
  • Meissa Vaccines
  • Melinta Therapeutics
  • MeMed
  • Menarini
  • Menarini Asia-Pacific
  • Merck and Co
  • Mereo BioPharma
  • Merit Medical Systems
  • Monaghan Medical
  • Morphic Therapeutic
  • Mount Sinai Health System
  • MSD
  • Mundipharma
  • Mylan Laboratories
  • Mylan Pharmaceuticals
  • NacuGen Therapeutics
  • National Health Service
  • National Heart
  • Lung and Blood Institute
  • National Institute of Allergy and Infectious Diseases
  • National Institute on Drug Abuse (NIDA)
  • National Institutes of Health
  • ndd Medical Technologies
  • Neos Therapeutics
  • NeuTec Pharma
  • New Amsterdam Sciences
  • Ninepoint Medical
  • Nippon Kayaku
  • NitricGen
  • Nitto BioPharma
  • Nitto Denko
  • Nonin Medical
  • Northern Biologics
  • Novare Pharmaceuticals
  • Novartis
  • Novici Biotech
  • NTC
  • Numedicus
  • NuMedii
  • Nuvo Pharmaceuticals
  • Olympus Respiratory America
  • Omdana Therapeutics
  • One BioMed
  • Orion
  • Owlstone Medical
  • Oxygen Plus
  • OxySure Systems
  • Pantherics
  • Paragonix Technologies
  • Parion Sciences
  • PARI Pharma
  • Patara Pharma
  • PatientsLikeMe
  • Peking University
  • Pernix Therapeutics
  • Perrigo
  • Pfizer
  • Pfizer Consumer Health
  • Pharmaxis
  • Pharmbio Korea
  • PharmEste
  • Philips
  • Pieris
  • Pillar Palatal
  • Polarean Imaging
  • Polyphor
  • Precision Image Analysis
  • Propeller Health
  • ProQR Therapeutics
  • Prosonix
  • Protectimmun
  • Pulmagen Therapeutics
  • Pulmatrix
  • Pulmonary Fibrosis Foundation (PFF)
  • Punjab Province
  • PureTech Health
  • Qiagen
  • QOL Devices
  • Qualcomm
  • Qualyst Transporter Solutions
  • Radboud University Nijmegen Medical Centre
  • ReadSense Genomic Center
  • Recipharm
  • Resmed
  • Respicardia
  • Respiratory Motion
  • rEVO Biologics
  • Revon Systems
  • Rhizen Pharmaceuticals
  • Roivant Sciences
  • Royal Philips Electronics
  • Samumed
  • Sanofi
  • Santhera Pharmaceuticals
  • Scholar Rock
  • Sciex
  • Seelos Therapeutics
  • Selvita
  • Sema4
  • Sensible Medical Innovations
  • SenzaGen
  • Seqirus
  • Serendex Pharmaceuticals
  • Serum Institute of India
  • Shire Pharmaceuticals
  • Siemens Healthineers
  • SI Pharmaceuticals
  • SkyePharma
  • Snoring Center USA
  • Sorin Group
  • Sorrento Therapeutics
  • SRETT
  • SteadyMed Therapeutics
  • Strand Life Sciences
  • Summa Health System
  • Sunovion Pharmaceuticals
  • Surgical Specialties
  • Sutter Health
  • Synairgen
  • Synergie Lyon Cancer
  • Synthetic Genomics
  • Takeda Pharmaceutical
  • TARGET PharmaSolutions
  • TB Alliance
  • Technology Strategy Board (UK)
  • Teijin
  • Teleflex
  • Teva Pharmaceutical Industries
  • TFS International
  • The Alfred Hospital
  • The Alpha-1 Project
  • Theravance
  • Thermo Fisher Scientific
  • Third Pole Therapeutics
  • TiGenix
  • toSense
  • Traffick Therapeutics
  • Tribute Pharmaceuticals
  • Tris Pharma
  • TSI Healthcare
  • UCB
  • United Therapeutics
  • University of British Columbia
  • University of California
  • San Diego
  • University of California San Francisco
  • University of Cambridge
  • University of Cincinnati
  • University of Colorado Denver
  • University of Dundee
  • University of Manchester
  • University of Maryland Baltimore
  • University of Michigan
  • University of North Carolina
  • University of Oxford
  • University of Pittsburgh
  • University of Rochester Medical Center
  • US Army
  • Vasomune Therapeutics
  • Vectura
  • VenatoRx
  • Veracyte
  • Verily
  • Vida Diagnostics
  • Videregen
  • Vital Connect
  • Vyaire Medical
  • Wal-Mart
  • Walter Reed Army Institute of Research
  • Watson Laboratories
  • Weill Cornell Medical College
  • Wellcome Trust Sanger Institute
  • Wellmed
  • Windtree Therapeutics
  • Wuxi STA
  • X-Rx
  • Xenios
  • XL-Protein
  • XOR-Labs Toronto
  • Xvivo Perfusion
  • Yale School of Medicine
  • Yale University
  • Yissum Research Development
  • YPrime
  • Yung Shin Pharm
  • ZAI Laboratory
  • ZappRx
  • Zelegent
Note: Product cover images may vary from those shown
Adroll
adroll